A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
暂无分享,去创建一个
Leroy Hood | Milton Datta | Paul Lange | Lawrence True | L. Hood | P. Nelson | R. Vessella | E. Gelmann | L. True | P. Lange | M. Datta | S. Hawley | R. Coleman | B. Knudsen | E. Mostaghel | T. Beer | Peter S Nelson | Beatrice Knudsen | Tomasz M Beer | Edward Gelmann | Ilsa Coleman | Sarah Hawley | Ching-Ying Huang | David Gifford | Roger Coleman | Elahe Mostaghel | Robert Vessella | Daniel Lin | David Gifford | Daniel Lin | Ilsa Coleman | Ching-Ying Huang | Sarah T. Hawley
[1] L. Bubendorf,et al. Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer , 2003, The Prostate.
[2] G. Mills,et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.
[3] A W Partin,et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. , 2000, Urology.
[4] D. Fryback,et al. Long-term survival among men with conservatively treated localized prostate cancer. , 1995, JAMA.
[5] T. Wheeler,et al. Growth and Survival Mechanisms Associated with Perineural Invasion in Prostate Cancer , 2004, Cancer Research.
[6] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. Vitiello,et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[9] E Helene Sage,et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.
[10] S. Hayward,et al. Role of stroma in carcinogenesis of the prostate. , 2002, Differentiation; research in biological diversity.
[11] D. Bostwick,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.
[12] M. Gleave,et al. YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity , 2004, The Prostate.
[13] P. McCullagh,et al. Generalized Linear Models , 1992 .
[14] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[15] S. Chetyrkin,et al. Characterization of a novel type of human microsomal 3alpha -hydroxysteroid dehydrogenase: unique tissue distribution and catalytic properties. , 2001, The Journal of biological chemistry.
[16] Pierre I Karakiewicz,et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Lander,et al. Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.
[18] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[19] J. Epstein,et al. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. , 2000, The American journal of surgical pathology.
[20] Tapio Visakorpi,et al. Amplification and Overexpression of Elongin C Gene Discovered in Prostate Cancer by cDNA Microarrays , 2002, Laboratory Investigation.
[21] R. Sutherland,et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma , 2003, Cancer.
[22] A. Partin,et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.
[23] R. Hruban,et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions , 2003, Oncogene.
[24] N. Tonks. Redox Redux: Revisiting PTPs and the Control of Cell Signaling , 2005, Cell.
[25] W. Isaacs,et al. Peroxisomal branched chain fatty acid β‐oxidation pathway is upregulated in prostate cancer , 2005, The Prostate.
[26] P. Nelson,et al. Digital expression profiles of the prostate androgen-response program , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[27] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[28] S. Dhanasekaran,et al. Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.
[29] P. Abrahamsson. Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.
[30] B. Mondovì,et al. Amine oxidases and tumors. , 2004, Neurotoxicology.
[31] H. Lilja,et al. Expression and immunolocalisation of neutral endopeptidase in prostate cancer. , 2003, European urology.
[32] James A Hanley,et al. Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.
[33] E. Yorida,et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells , 2005, Oncogene.
[34] E. Bergstralh,et al. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ‐confined prostate cancer , 2002, Genes, chromosomes & cancer.
[35] Sang Won Kang,et al. Peroxiredoxins in breast carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] C. Supuran,et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. , 2005, European urology.
[37] M. Kattan,et al. Assessment of the biologic markers p53, ki‐67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery , 1998 .
[38] G. Sledge,et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.
[39] Jeffrey A. Magee,et al. Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.
[40] Eric R. Ziegel,et al. Generalized Linear Models , 2002, Technometrics.